S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
Log in

NASDAQ:KMPH - KemPharm Stock Price, Forecast & News

$0.40
+0.03 (+8.22 %)
(As of 12/11/2019 04:00 PM ET)
Today's Range
$0.36
Now: $0.40
$0.42
50-Day Range
$0.36
MA: $0.48
$0.59
52-Week Range
$0.33
Now: $0.40
$2.89
Volume287,196 shs
Average Volume179,477 shs
Market Capitalization$13.12 million
P/E RatioN/A
Dividend YieldN/A
Beta1.32
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder. It also provides APADAZ, an immediate-release combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KMPH
CUSIPN/A
Phone321-939-3416

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($2.52) per share

Profitability

Net Income$-56,470,000.00

Miscellaneous

Employees33
Market Cap$13.12 million
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive KMPH News and Ratings via Email

Sign-up to receive the latest news and ratings for KMPH and its competitors with MarketBeat's FREE daily newsletter.


KemPharm (NASDAQ:KMPH) Frequently Asked Questions

What is KemPharm's stock symbol?

KemPharm trades on the NASDAQ under the ticker symbol "KMPH."

How were KemPharm's earnings last quarter?

KemPharm Inc (NASDAQ:KMPH) released its earnings results on Thursday, November, 14th. The specialty pharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.28) by $0.34. The specialty pharmaceutical company earned $11.46 million during the quarter. View KemPharm's Earnings History.

When is KemPharm's next earnings date?

KemPharm is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for KemPharm.

What price target have analysts set for KMPH?

3 analysts have issued 1 year target prices for KemPharm's stock. Their forecasts range from $1.05 to $3.00. On average, they expect KemPharm's share price to reach $2.18 in the next twelve months. This suggests a possible upside of 452.7% from the stock's current price. View Analyst Price Targets for KemPharm.

What is the consensus analysts' recommendation for KemPharm?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KemPharm in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for KemPharm.

What are Wall Street analysts saying about KemPharm stock?

Here are some recent quotes from research analysts about KemPharm stock:
  • 1. According to Zacks Investment Research, "KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. " (11/23/2019)
  • 2. HC Wainwright analysts commented, "Our $3 12-month target is based on a 65% probability of success adjusted DCF including profit split from Apadaz—approved and partnered prodrug of IR hydrocodone, pilot launching in 2H19—and royalties and milestones from KP415 from partner GPC. We project peak $23M KP415 revenue to KMPH at 100% gross margins. Both have IP into the 2030s. We see most near-term revenue solely from milestones, before product royalties and profit share accelerate in 2022-2023, with KemPharm sustainable profitability in 2023." (9/5/2019)

Has KemPharm been receiving favorable news coverage?

Media stories about KMPH stock have trended somewhat negative on Wednesday, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. KemPharm earned a daily sentiment score of -1.1 on InfoTrie's scale. They also gave press coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for KemPharm.

Are investors shorting KemPharm?

KemPharm saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 339,600 shares, an increase of 50.3% from the October 31st total of 226,000 shares. Based on an average trading volume of 217,700 shares, the days-to-cover ratio is presently 1.6 days. Currently, 1.3% of the shares of the company are short sold. View KemPharm's Current Options Chain.

Who are some of KemPharm's key competitors?

What other stocks do shareholders of KemPharm own?

Who are KemPharm's key executives?

KemPharm's management team includes the folowing people:
  • Dr. Travis C. Mickle, Co-Founder, Chairman, Pres & CEO (Age 46)
  • Dr. Sven Guenther, Exec. VP of R&D (Age 47)
  • Mr. Gordon K. Johnson, Chief Bus. Officer (Age 67)
  • Ms. Christal M. M. Mickle, Co-Founder and VP of Operations & Product Devel. (Age 40)
  • Mr. R. LaDuane Clifton CPA, CFO, Sec. & Treasurer (Age 47)

When did KemPharm IPO?

(KMPH) raised $60 million in an initial public offering on Thursday, April 16th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.

Who are KemPharm's major shareholders?

KemPharm's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include RDA Financial Network (0.48%) and Wedbush Securities Inc. (0.33%). Company insiders that own KemPharm stock include Daniel L Cohen, Delaware Street Capital Master, Gordon K Johnson, R Laduane Clifton, Timothy J Sangiovanni and Travis C Mickle. View Institutional Ownership Trends for KemPharm.

Which institutional investors are buying KemPharm stock?

KMPH stock was purchased by a variety of institutional investors in the last quarter, including RDA Financial Network and Wedbush Securities Inc.. Company insiders that have bought KemPharm stock in the last two years include Daniel L Cohen, Delaware Street Capital Master, Gordon K Johnson, R Laduane Clifton, Timothy J Sangiovanni and Travis C Mickle. View Insider Buying and Selling for KemPharm.

How do I buy shares of KemPharm?

Shares of KMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is KemPharm's stock price today?

One share of KMPH stock can currently be purchased for approximately $0.40.

How big of a company is KemPharm?

KemPharm has a market capitalization of $13.12 million. The specialty pharmaceutical company earns $-56,470,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. KemPharm employs 33 workers across the globe.View Additional Information About KemPharm.

What is KemPharm's official website?

The official website for KemPharm is http://www.kempharm.com/.

How can I contact KemPharm?

KemPharm's mailing address is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. The specialty pharmaceutical company can be reached via phone at 321-939-3416 or via email at [email protected]


MarketBeat Community Rating for KemPharm (NASDAQ KMPH)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  309 (Vote Outperform)
Underperform Votes:  208 (Vote Underperform)
Total Votes:  517
MarketBeat's community ratings are surveys of what our community members think about KemPharm and other stocks. Vote "Outperform" if you believe KMPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KMPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Featured Article: How mutual funds make money

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel